1. Boye E, Yu Y, Paranya G, Mulliken JB, Olsen
BR, Bischoff J. Clonality and altered behavior of endothelial cells
from hemangiomas. J Clin Invest. 2001;107(6):745-752.
2. Drolet BA, Esterly NB, Frieden IJ. Hemangiomas in children. N
Engl J Med. 1999;341(26):173-180.
3. Frieden IJ, Haggstrom AN, Drolet BA, et al. Infantile hemangiomas:
current knowledge, future directions. Proceedings of a research
workshop on infantile hemangiomas. Pediatr Dermatol.
2005;22(5):383-406.
4. North P, Waner M, Mizeracki A, Mihm MC Jr. GLUT 1: A newly
discovered immunohistochemical marker for juvenile hemangiomas. Hum
Pathol. 2000;31(1):11-22.
5. Haggstrom AN, Drolet BA, Baselga E, et al. Prospective study
of infantile hemangiomas, part II: clinical characteristics predicting
complications and treatment. Pediatrics. 2006;118(3):882-887.
6. Barrio VR, Drolet BA. Treatment of hemangiomas of infancy.
Dermatol
Ther. 2005; 18(2):151-159.
[PubMed: 15953144]
7. Akyuz C, Yaris N, Kutluk MT, Buyukpamukcu M. Management of
cutaneous hemangiomas: a retrospective analysis of 1109 cases and
comparison of conventional does
prednisolone with high-dose methylprednisolone
therapy.
Pediatr Hematol Oncol. 2001;18(1):47-55.
8. Mulliken JB, Boon LM, Takahashi K. Pharmacologic therapy
for endangering hemangiomas. Curr Opin Dermatol.
1995;2(1):109-113.
9. Ranchod TM, Frieden IJ, Fredrick DR. Corticosteroid treatment
of periorbital haemangioma of infancy: a review of the evidence. Br
J Ophthalmol. 2005;89(9):1134-1138.
10. Bennett ML, Fleischer AB Jr, Chamlin SL, Frieden IJ. Oral
corticosteroid use is effective for cutaneous hemangiomas: an evidence-based
evaluation. Arch Dermatol. 2001;137(9):1208-1213.
11. Ezekowitz RA, Mulliken JB, Folkman J. Interferon alfa-2a
therapy for life-threatening hemangiomas of infancy. N Engl
J Med. 1992;326(22):1456-1463.
12. Bauman NM, Burke DK, Smith RJ. Treatment of massive or life-threatening
hemangiomas with recombinant alpha(2a)-interferon. Otolaryngol
Head Neck Surg. 1997;117(1):99-110.
13. Greinwald JH Jr, Burke DK, Bonthius DJ, Bauman NM, Smith
RJ. An update on the treatment of hemangiomas in children with interferon
alfa-2a. Arch Otolaryngol Head and Neck Surg. 1999;125(1):21-27.
14. Michaund AP, Bauman NM, Burke DK, Manaligod JM, Smith RJ.
Spastic diplegia and other motor disturbances in infants receiving
interferon-alpha. Laryngoscope. 2004;114(7):1231-1236.
15. Adams DM, Orme L, Bowers D. Vincristine treatment of complicated
hemangiomas. International Society for the Study of Vascular Anomalies
(ISSVA) 14th International Workshop on Vascular Anomalies, Netherlands;
June 2002.
16. Enjolras O, Breviere GM, Rogers G. Vincristine treatment
for function- and life-threatening infantile hemangioma. Arch
Pediatr. 2004;11(2):99-107.
17. Fawcett SL, Grant I, Hall PN, Kelsall AW, Nicholson JC.
Vincristine as a treatment for a large haemangioma threatening vital
functions. Br J Plast Surg. 2004;57(2):168-171.
18. Moore J, Lee M, Garzon M, et al. Effective therapy of a
vascular tumor of infancy with vincristine. J Pediatr Surg. 2001:36(8):1273-1276.
19. McCahon EA. Treatment of hemangiomas in children with vincristine.
International Society for the Study of Vascular Anomalies (ISSVA)
16th International Workshop on Vascular Anomalies. Milan, Italy;
June 14-17, 2006.
20. Isaacs H Jr. Fetal and neonatal hepatic tumors. J
Pediatric Surg. 2007;42(11):1789-1803.
21. Sari N, Yalcin B, Akuyuz C, Haliloglu M, Buyukpamukcu M.
Infantile hepatic hemangioendothelioma with elevated serum alpha-fetoprotein. Pediatr
Hematol Oncol. 2006;23(8):639-647.
22. Christison-Lagay ER, Burrows PE, Alomari A, Dubois J, Kozakewich
HP, Lane TS. Hepatic hemangiomas: subtype classification and development
of a clinical algorithm and registry. J Pediatr Surg. 2007;42(1):62-67.
23. Huang SA, Tu HM, Harney JW, et al. Severe hypothyroidism
caused by type 3 iodothyronine deiodinase in infantile hemangiomas. N
Engl J Med. 2000;343(3):185-189.
24. Perkins P, Weiss SW. Spindle cell hemangioendotheliomas:
an analysis of 78 cases with reassessment of its pathogenesis and
biological behavior.
Am J Surg Pathol. 1996;20:1196-1204.
[PubMed: 8827025]
25. Fletcher CDM, Beham A, Schmid C. Spindle cell hemangioendotheliomas:
a clinicopathological and immunohistochemical study indicative of
a non-specific neoplastic lesion.
Histopathology. 1991;18:291-301.
[PubMed: 2071088]
26. Swerlick R, Cooper P. Pyogenic granuloma (lobular capillary
hemangioma) within port wine stains. J Am Acad Dermatol. 1983;8(5):627-630.
27. Campbell JP, Grekin RC, Ellis CN, Matsuda-John SS, Swanson
NA, Voorhees JJ. Retinoid therapy is associated with excess granulation
tissue responses. J Am Acad Dermatol. 1983;9(5):708-713.
28. Mills SE, Cooper PH, Fechner RE. Lobular capillary hemangioma:
the underlying lesion of pyogenic granuloma. A study of 73 cases
from the oral and nasal mucous membranes. Am J Surg Pathol.
1980;4(5):470-479.
29. Coutinho-Camillo CM, Brentani MM, Nagai MA. Genetic alterations
in juvenile nasopharyngeal angiofribromas. Head Neck.
2008;30(3):390-400.
30. Darouti MEL, Marzouk SA, Sobhi RM, Bassiouni DA. Retiform
hemangioendothelioma. Int J Dermatol. 2000;39(5):363-382.
31. Lyons LL, North PE, Mac-Moune Lai F, Stoler MH, Folpe AL,
Weiss SW. Kaposiform hemangioendothelioma: a study of 33 cases emphasizing
its pathologic, immunophenotypic, and biologic uniqueness from juvenile
hemangioma. Am J Surg Pathol. 2004;28(5):559-568.
32. Sarkar M, J B Mulliken, Kosakewich HP. Thrombocytopenic
coagulopathy (Kasabach-Merritt phenomenon) is associated with Kaposiform
hemangioendothelioma and not with common infantile hemangioma. Plast
Reconstr Surg. 1997;100(6):1377-1386.
33. Enjolras O, M Wassef, Mazoyer E. Infants with Kasabach-Merritt
syndrome do not have “true” hemangiomas. J
Pediatr. 1997;130(4):631-640.
34. Mulliken JB, Anupindi S, Ezekowitz RAB, Phil D, Mihm M.
Case 13-2004: a newborn girl with a large cutaneous lesion, thrombocytopenia,
and anemia. N Engl J Med. 2004;350(17):1764-1775.
35. Haisley-Royster C, Enjolras O, Frieden J, et al. Kasabach-Merritt
phenomenon: a retrospective study of treatment with vincristine. J
Pediatr Hematol Oncol. 2002;24(6):459-462.
36. Hauer J, Graubner U, Konstantopoulos N, Schmidt S, Pflunger
T, Schmid I. Effective treatment of kaposiform hemangioendotheliomas
associated with Kasabach-Merritt phenomenon using four-drug regimen. Pediatr
Blood Cancer. 2007;49(6):852-854.
37. Enjolras O, Mulliken JB, Wassef M, et al. Residual lesions
after Kasabach-Merritt phenomenon in 41 patients. J Am Acad
Dermatol. 2000;42(2):225-235.
38. Weiss SW, Enzinger FM. Epithelioid hemangioendothelioma
a vascular tumor often mistaken for a carcinoma. Cancer.
1982;50(5):970-981.
39. Mehrabi A, Kashfi A, Fonauni H, et al. Primary malignant
hepatic epithelioid hemangioendothelioma: a comprehensive review
of the literature with emphasis on the surgical therapy. Cancer. 2006;107(9):2108-2121.
40. Rodriguez-Galindo C, Ramsy K, Jenkins JJ, et al. Hemangiopericytoma
in children and infants. Cancer. 2000;88(1):198-204.
41. Ferrari A, Casanova M, Bisogno G, et al. Hemangiopericytoma
in pediatric ages. Cancer. 2001;92(10):2692-2698.
42. Metzel T, Calonje E, Nascimento AJ, Fletcher CDM. Infantile
hemangiopericytoma versus infantile myofibromatosis. study of a
series suggesting a continuous spectrum of infantile myofibroblastic
lesions. Am J Surg Pathol. 1994;18 (9):922-930.
43. Lezama-del Valle P, Gerald WL, Tsai J, et al. Malignant
vascular tumors in young patients. Cancer. 1998;83(8):1634-1639.
44. Budd GT. Management of angiosarcoma. Curr Oncol
Rep. 2002;4(6):515-519.
45. Fayette J, Martin E, Piperno-Neumann S, et al. Angiosarcomas,
a heterogeneous group of sarcomas with specific behavior depending
on primary site: a retrospective study of 161 cases. Ann
Oncol. 2007;18(12):2030-2036.